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Purpose: Treatment continuation is considered an important measure of antipsychotic 
  effectiveness in schizophrenia, reflecting the medication’s efficacy, safety, and tolerability from 
both patients’ and clinicians’ perspectives. This study identified characteristics of patients with 
schizophrenia who continue olanzapine therapy for a 1-year period in Japan.
Methods: In a large (N = 1850), prospective, observational study, Japanese patients with 
schizophrenia who initiated treatment with olanzapine were followed for 1 year. Baseline 
  characteristics were compared using t-tests and chi-square tests. Stepwise logistic regression 
was used to identify independent baseline predictors of treatment continuation.
Results: Most patients (68.2%) continued with olanzapine therapy for the full 1-year study 
period, with an average duration of 265.5 ± 119.4 days. At baseline, patients who continued were 
significantly more likely to be male, older, and inpatients; have longer illness duration, higher 
negative and cognitive symptoms, better health-related quality of life, and prior anticholinergic 
use. Continuers were significantly less likely to engage in social activities, live independently, 
work for pay, or have prior antidepressant use. Continuers showed significantly greater early 
(3-month) improvement in global symptom severity. Logistic regression found that continuation 
was significantly predicted by longer illness duration, lower positive symptoms, higher negative 
symptoms, and better health-related quality of life.
Conclusions: In this large naturalistic study in Japan, most patients with schizophrenia stayed 
on olanzapine therapy for the full 1-year study period. Treatment completion with olanzapine was 
independently predicted by longer illness duration, lower positive symptoms, higher   negative 
symptoms, and better health-related quality of life.
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Introduction
Schizophrenia is a chronic and disabling mental illness that is associated with cognitive, 
behavioral, social, and occupational impairments.1 The primary recommended 
treatment for the acute symptoms of schizophrenia is antipsychotic medication.2,3 
When assessing outcomes from treatment with antipsychotic medication, a variety of 
domains have been studied, including the core symptoms of schizophrenia,4–6 functional 
outcomes,7,8 cognition,9,10 and health care resource use.11,12 However, a simple measure 
of treatment effectiveness that is relevant to different stakeholders and broadly reflects 
meaningful outcomes in usual clinical care is needed.
One overall measure of effectiveness for antipsychotic treatment outcome 
in schizophrenia is time to all-cause medication discontinuation, a measure that 
  captures the medication’s efficacy, safety, and tolerability from both patients’ and   Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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physicians’ perspectives.13,14 The Clinical Antipsychotic 
Trials of Intervention Effectiveness, a large, independent, 
publicly funded, randomized clinical trial in the USA, used 
time to all-cause medication discontinuation as its primary 
outcome variable.13,15 Similarly, the European First Episode 
Schizophrenia Trial also used this as the study’s primary 
outcome variable.16 Patients who continue with an anti-
psychotic longer have been shown to have better clinical 
and functional outcomes and a reduced risk of relapse and 
hospitalization.12,13,17,18
Multiple studies have demonstrated that medica-
tion discontinuation is sensitive to differences in out-
comes between antipsychotics. Olanzapine therapy in 
  particular, has shown significantly lower rates of discon-
tinuation than ziprasidone,13,15,19–22 quetiapine,13,15,21,23–29 
risperidone,11–13,19,24,26,30–37 aripiprazole,4,27,38 as well as typical 
antipsychotics.7,9–12,13,16,19,24,26,35,39–44
Few studies have attempted to identify baseline 
characteristics of patients who stay longer on therapy in 
Japan. Previous studies outside of Japan have identified 
predictors of antipsychotic continuation in schizophrenia such 
as male gender,28,45,46 older age,13,25,28,47,48 fewer psychiatric 
hospitalizations,28 lack of substance-use disorder,47,49,50 better 
therapeutic alliance,49 greater reduction in symptoms,17,18 
and greater improvements in health-related quality of 
life (HRQOL).17,18 Whether these findings generalize to 
the Japanese health care system, which utilizes inpatient 
treatment relatively frequently,51,52 is unclear. Using data 
from a 1-year naturalistic observational study of patients with 
schizophrenia in Japan, this study aimed to identify baseline 
characteristics that differentiate patients who completed 
1 year of olanzapine therapy from patients who discontinued 
olanzapine therapy.
Methods
sample selection
The data for this study came from the Olanzapine Post 
Marketing Surveillance (OPMS) study. OPMS was a large 
multicenter naturalistic 1-year study that took place in Japan 
and consisted of 1850 patients who met the study entry 
criteria. To be eligible to take part in the study, participants 
had to have been diagnosed with schizophrenia and to 
have initiated treatment with olanzapine. The diagnosis for 
schizophrenia was based on criteria in the fourth edition of 
the Diagnostic and Statistical Manual of Mental Disorders 
published by the American Psychiatric Association.1 During 
this naturalistic study, all treatment decisions, including the 
decision to initiate olanzapine, were left to the discretion of 
the treating physician. Study enrollment started in November 
2003 and was completed in July 2004. The follow-up period 
for the study continued for 1 year after enrollment or until the 
patient discontinued the treatment with olanzapine. Data were 
collected at the baseline, 3-month, 6-month, and 12-month 
visits. The procedures were approved by the internal review 
boards at each of the participating institutions. Informed 
consent for this observational study was acquired based on 
the requirements at each institution.
Measures and definitions
The primary dependent variable in this study was a 
dichotomous variable indicating if a patient continued with 
or discontinued olanzapine before the end of the 1-year study. 
Patients who left the study were classified as discontinuing 
olanzapine.
In this observational study, simple noninvasive measures 
were chosen to limit interference with usual clinical practice. 
Patient symptomatology was measured using the Clinical 
Global Impression-Schizophrenia (CGI-SCH) scale. The 
CGI-SCH scale consists of ratings for positive, negative, 
  cognitive, and depressive symptoms as well as a global 
  severity rating.53 The ratings for the CGI-SCH scale are 
anchored and range from no symptoms (0) to severe 
  symptoms (6).53 Assessment of the concurrent validity between 
the CGI-SCH and the Positive and Negative Syndrome Scale 
found that the validity coefficients ranged from 0.61 for 
depressive symptoms to 0.86 for positive symptoms, with 
the remaining coefficients ranging from 0.75–0.80.54
Consistent with prior research, treatment response 
was operationally defined based on the CGI-SCH Global 
  Severity rating.55 For patients with a baseline score between 
4 and 6 points, treatment response was defined as a 2-point 
improvement. For patients with a baseline score between 
1 and 3, treatment response was defined as a 1-point 
improvement.
HRQOL was assessed using the European Quality of 
Life 5-Dimensions Visual Analog Scale (EQ-5D VAS).56 
The EQ-5D VAS ranges from 0 to 100 and has demonstrated 
moderate concurrent validity (ranging from 32 to 62) with 
the various scales of the World Health Organization Quality 
of Life – Brief instrument.57
Prior medication use was coded with indicator variables 
(Yes/No) for each of the following medication classes: 
antipsychotics, anticholinergics, antidepressants, anxiolytics/
hypnotics, mood stabilizers, or other. The presence of a 
baseline medical comorbidity was coded based on the 
presence of any of the following conditions: hypertension, Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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hyperlipidemia, hepatic dysfunction, renal dysfunction, 
or other. Participation in social activities was coded if the 
patient indicated they had participated in any social activities 
in the past 4 weeks. Working for pay was coded if the 
patient indicated working with income at baseline. Finally, 
living independently was coded if the patient indicated living 
independently at baseline rather than being hospitalized, 
homeless, living communally with persons caring for the 
patient, or living as a dependent family member.
statistical methods
Differences in baseline patient characteristics were compared 
using t-tests for continuous variables and chi-square tests for 
categorical variables. Stepwise logistic regression was used 
to identify independent baseline predictors of continuing 
olanzapine therapy. Table 1 lists all of the baseline predictor 
variables available to the stepwise logistic regression model. 
However, the CGI-SCH Global Severity scale was excluded 
from the stepwise logistic regression due to multicolinearity 
with the subscales. The significance level was set at α = 0.05 
and all analyses were completed using SAS 9.1.3 (SAS 
Institute Inc, Cary, NC).
Results
sample description
The OPMS study registered and enrolled 1949 patients. This 
analysis utilized the 1850 (94.9%) patients who met all study 
entry criteria: 27 were excluded for contract or registration 
violations, 20 had no case report forms, 49 did not return 
after the initial visit, and three did not initiate treatment with 
olanzapine. The baseline characteristics of this sample can 
be seen in Table 1. For the entire sample, the average age 
was 44.8 ± 15.5 years, 53.2% were male, 43.2% initiated 
olanzapine in an outpatient setting, and the average duration 
of illness was 18.3 ± 14.7 years. Most participants (68.2%; 
1262/1850) continued the olanzapine treatment for the full 
Table 1 Baseline univariate characteristics
Characteristic Total N Discontinuer 
(N = 588)
Continuer 
(N = 1262)
P
Demographics
Age (y), mean ± sD 1850 42.4 ± 15.5 45.9 ± 15.4 ,0.001
Female (%) 1850 51.0 44.8 0.013
Clinical status
Outpatient status (%) 1850 49.3 40.4 ,0.001
Duration of illness (y), mean ± sD 1451 15.1 ± 14.0 19.7 ± 14.9 ,0.001
Tardive dyskinesia (%) 1822 5.2 7.7 0.052
BMi (kg/m2), mean ± sD 1638 22.6 ± 4.3 22.6 ± 4.0 0.84
Any medical comorbidities (%) 1849 31.5 38.4 0.004
Clinical measures
cgi-sch global severity, mean ± sD 1822 3.3 ± 1.0 3.4 ± 1.1 0.45
cgi-sch positive, mean ± sD 1822 3.1 ± 1.5 2.9 ± 1.5 0.052
cgi-sch negative, mean ± sD 1822 2.9 ± 1.4 3.2 ± 1.3 ,0.001
cgi-sch cognitive, mean ± sD 1822 2.8 ± 1.4 3.0 ± 1.3 0.004
cgi-sch depressive, mean ± sD 1822 1.7 ± 1.4 1.6 ± 1.3 0.09
responded at 3-month visit (%) 1822 28.9 36.0 0.003
Functional measures
eQ-5D VAs, mean ± sD 1815 43.6 ± 21.3 49.6 ± 22.8 ,0.001
Working for pay (%) 1820 12.0 7.5 0.007
social activities (%) 1820 32.7 26.8 0.027
Living independently (%) 1822 20.4 15.7 0.014
Baseline and prior medication use
starting dose of OLZ (mg/day), mean ± sD 1847 8.4 ± 5.3 8.6 ± 5.0 0.56
switch from atypical antipsychotic (%) 1850 21.6 20.5 0.60
switch from typical antipsychotic (%) 1850 13.3 15.2 0.27
Prior anticholinergic use (%) 1823 35.7 41.8 0.012
Prior antidepressant use (%) 1823 7.7 4.4 0.005
Prior anxiolytic/hypnotic use (%) 1823 57.6 60.5 0.24
Prior mood stabilizer use (%) 1823 13.0 12.9 0.93
Prior other medication use (%) 1823 32.2 44.9 ,0.001
Abbreviations: BMi, body mass index; cgi-sch, clinical global impression-schizophrenia; eQ-5D VAs, european Quality of Life 5-Dimensions Visual Analog scale;   
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1-year study, while 31.8%; (588/1850) discontinued the 
study at some point (see Figure 1). The mean duration of 
olanzapine therapy during the 1-year study treatment was 
265.5 ± 119.4 days.
Univariate comparisons between 
discontinuers and continuers
Table 1 contrasts the baseline characteristics of patients who 
completed the 1-year study with olanzapine (continuers) 
with those who discontinued olanzapine treatment prior to 
the end of the study (discontinuers). Significant differences 
were observed in multiple demographics, clinical status 
variables, symptom measures, functional measures, and prior 
medication use variables (see Table 1).
Multivariate comparisons between 
discontinuers and continuers
Stepwise logistic regression was used to identify independent 
predictors of continuation. The odds ratios and confidence 
intervals for the final version of the stepwise logistic 
regression model are presented in Figure 2. Overall, the 
model was modestly accurate in differentiating patients who 
would continue or discontinue treatment with olanzapine 
(c-statistic = 0.635). The c-statistic indicated that the model 
could accurately classify a randomly selected continuer 
from a randomly selected discontinuer 63.5% of the time. 
Continuation was independently predicted by lower positive 
symptoms, higher negative symptoms, longer illness duration, 
and better HRQOL. All of the significant predictors were 
continuous variables; therefore, the odds ratios represent the 
change in odds of continuation for every one-unit increase in 
the predictor. For example, for every year that a patient had 
been diagnosed with schizophrenia, the odds of continuing 
with olanzapine increased by a factor of 1.01.
Finally, early change in CGI-SCH Global Severity, 
defined as the difference between baseline and the first 
visit (3 months), was compared between the continuers and 
discontinuers. Patients who continued with olanzapine treat-
ment experienced greater improvements (decreases) in CGI-
SCH Global Severity compared to those who discontinued 
olanzapine therapy (−0.69 vs −0.53; P = 001).
Discussion
In this large naturalistic observational study of patients 
with schizophrenia in Japan, most patients (68.2%) 
continued olanzapine therapy for the full 1-year study, 
with an average time to discontinuation of 265.5 days. 
A large number of baseline characteristics predicted the 
continuation in the univariate analyses, but only a few 
were found to be independent predictors in the multivariate 
analysis. In the stepwise logistic regression model, higher 
EQ-5D VAS scores, longer duration of illness, higher CGI-
SCH negative scores, and lower CGI-SCH positive scores 
were significant predictors of treatment continuation. 
The olanzapine continuers had significantly greater early 
improvements in CGI-SCH Global Severity scores than 
the discontinuers.
The findings in the current study are consistent with 
some past schizophrenia research with outpatients outside 
of Japan. In the univariate analysis, older age13,25,27,47,48 and 
male gender28,44,46 predicted antipsychotic continuation. The 
primary findings in the multivariate analysis were also con-
sistent with previous research on predictors of medication 
  continuation: longer duration of illness,45 higher baseline 
HRQOL,58 higher baseline negative symptoms,58 and lower 
baseline positive symptoms59 have all been identified as pre-
dictors of antipsychotic continuation. Interestingly, in one 
study, lower baseline positive symptoms were reported to 
predict discontinuation rather than continuation.48 Inconsisten-
cies in predictors of continuation may be a result of differences 
in study methodologies, outcome variables, the inclusion of 
inpatients, study population, or health care systems.
In addition to the identified patients’ baseline charac-
teristics, poorer efficacy of antipsychotic medications has 
also been linked to the discontinuation of treatment. In fact, 
past research has consistently identified lack of   efficacy 
as being one of the primary reasons for antipsychotic   
discontinuation.13,17,21,26,45,60–63 Consistent with prior research, 
secondary analysis in the present study found that patients 
who continued antipsychotic treatment had greater reduc-
tions in symptoms.
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Figure 1 Proportion of patients continuing olanzapine for 1 year. Most patients 
(68.2%, 1262/1850) continued with olanzapine treatment for the full 1-year study.
Note: The mean duration of olanzapine treatment was 265.5 ± 119.4 days.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Limitations
Although a large number of predictors were used in this anal-
ysis, some potentially important predictors of antipsychotic 
persistence were not included in this study. A lower level of 
substance abuse has been frequently demonstrated as being 
an important predictor of antipsychotic persistence.47,49,50,63–67 
Additionally, insight into illness67 as well as positive attitudes 
toward medication49,68 have been identified as being poten-
tially important in the predictors of antipsychotic persistence. 
The primary focus of this analysis was on baseline predic-
tors of later antipsychotic persistence. Changes in metabolic 
and other tolerability parameters were not included in the 
analyses and may be important predictors of antipsychotic 
persistence. Furthermore, the OPMS study focused only on 
olanzapine-treated patients with schizophrenia in Japan, so 
the findings may not generalize to other antipsychotics or 
geographic locations.
Conclusion
Consistent with prior research, patients who continued 
olanzapine therapy were more likely to experience signifi-
cant improvements in clinical outcomes compared to those 
who discontinued treatment.18,69 In addition, patients with 
certain baseline characteristics appear to be more likely to 
continue with olanzapine treatment for a longer period of 
time. Stepwise logistic regression revealed that, compared to 
discontinuers, those who continued with olanzapine therapy 
had significantly longer illness duration, lower baseline 
positive symptoms, higher baseline negative symptoms, and 
higher baseline HRQOL. Identifying these characteristics has 
clinical implications in usual care in Japan, as they may be 
useful in early detection of schizophrenia patients who could 
benefit from targeted interventions aimed at improving their 
persistence with medication, thus increasing the chance for 
better long-term treatment outcomes.
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